Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Maryland Tech Journal.
Press releases published on July 7, 2025
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
GlobeNewswire
·
July 7, 2025
Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development …
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
GlobeNewswire
·
July 7, 2025
In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions. Biomarker …
Denodo Announces Plans to Further Support AI Innovation by Releasing Denodo DeepQuery, a Deep Research Capability
GlobeNewswire
·
July 7, 2025
PALO ALTO, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Denodo, a leader in data management, announced the availability of the Denodo DeepQuery capability, now as a private preview, and generally available soon, enabling generative AI (GenAI) to go beyond …
Descartes MacroPoint™ FraudGuard 2.0 Provides Transportation Industry with Next-Generation Solution for Freight Fraud Defense
GlobeNewswire
·
July 7, 2025
ATLANTA, July 07, 2025 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced the release of Descartes MacroPoint™ FraudGuard 2.0, the latest advancement in …
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
GlobeNewswire
·
July 7, 2025
APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted) at Week 16, the highest topline and placebo- …
Ambow Unveils HybriU Knowledge Capture: Securing Organizational Knowledge for the Future
GlobeNewswire
·
July 7, 2025
CUPERTINO, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Ambow Education Holding Ltd. (NYSE American: AMBO), a leading global provider of AI-driven education and collaboration technology, today announced the launch of HybriU Knowledge Capture, a strategic …
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
GlobeNewswire
·
July 7, 2025
- Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults - KUALA LUMPUR, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: …
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
GlobeNewswire
·
July 7, 2025
Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it has entered into an …
PathMaker Neurosystems Announces Publication of First Study Demonstrating Increased Survival in an ALS Mouse Model After Treatment With Non-Invasive Neuromodulation
GlobeNewswire
·
July 7, 2025
Boston, MA and Providence, RI, July 07, 2025 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neurotechnology company developing a breakthrough non-invasive approach for treating Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig …
First patient dosed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy
GlobeNewswire
·
July 7, 2025
PARIS, July 07, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first patient has been …
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe
GlobeNewswire
·
July 7, 2025
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe A new report reveals that biosolutions could generate EUR 133 billion in economic gains and create over 600,000 jobs across all of Europe by 2035. But …
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers
GlobeNewswire
·
July 7, 2025
First-in-human administration of CPV-104 marks a major step in drug development for the company’s lead compound (Factor H) and in bringing a new medication to patients Freiburg im Breisgau, Germany, July 7, 2025 – Eleva, a pioneer in discovering and …
Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health
GlobeNewswire
·
July 7, 2025
SHELTON, Conn., July 06, 2025 (GLOBE NEWSWIRE) -- Abinopharm, Inc., an innovative nutritional and biopharmaceutical company based in Shelton, Connecticut, USA, is pleased to announce that its partner, EGT Synbio, headquartered in Shanghai, China, has …
Ripple is applying for a national bank charter, LET Mining creates more value for XRP holders
GlobeNewswire
·
July 7, 2025
New York City, NY, July 06, 2025 (GLOBE NEWSWIRE) -- Ripple (XRP) has ended its battle with the U.S. Securities and Exchange Commission (SEC) and is getting rid of the supervision of the U.S. Securities and Exchange Commission (SEC). Garlinghouse tweeted: …